To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
9 novembre 2016 aggiornato da: Boehringer Ingelheim
An Exploratory, 12 Week, Randomised, Partially Double-blinded, Placebo-controlled Parallel Group Trial to Explore the Effects of Once Daily Treatments of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination or Tiotropium (Both Delivered by Respimat® Inhaler), Supervised Exercise Training and Behavior Modification on Exercise Capacity and Physical Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objectives of the study are to explore the effect of treatment with orally inhaled tiotropium + olodaterol fixed dose combination with and without exercise training, and tiotropium comparing to placebo, on top of behavioural modification in improving exercise capacity in patients with COPD
Panoramica dello studio
Stato
Completato
Condizioni
Tipo di studio
Interventistico
Iscrizione (Effettivo)
304
Fase
- Fase 3
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
South Australia
-
Daw Park, South Australia, Australia
- Boehringer Ingelheim Investigational Site
-
Glen Osmond, South Australia, Australia
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Salzburg, Austria
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Genk, Belgio
- Boehringer Ingelheim Investigational Site
-
Hasselt, Belgio
- Boehringer Ingelheim Investigational Site
-
Leuven, Belgio
- Boehringer Ingelheim Investigational Site
-
-
-
-
Quebec
-
Montreal, Quebec, Canada
- Boehringer Ingelheim Investigational Site
-
Ste-Foy, Quebec, Canada
- Boehringer Ingelheim Investigational Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kolding, Danimarca
- Boehringer Ingelheim Investigational Site
-
København NV, Danimarca
- Boehringer Ingelheim Investigational Site
-
Odense, Danimarca
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site
-
Bochum, Germania
- Boehringer Ingelheim Investigational Site
-
Frankfurt, Germania
- Boehringer Ingelheim Investigational Site
-
Großhansdorf, Germania
- Boehringer Ingelheim Investigational Site
-
Heidelberg, Germania
- Boehringer Ingelheim Investigational Site
-
Leverkusen, Germania
- Boehringer Ingelheim Investigational Site
-
Solingen, Germania
- Boehringer Ingelheim Investigational Site
-
Teuchern, Germania
- Boehringer Ingelheim Investigational Site
-
Tübingen, Germania
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Greenlane East Auckland NZ, Nuova Zelanda
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Gdansk, Polonia
- Boehringer Ingelheim Investigational Site
-
Lodz, Polonia
- Boehringer Ingelheim Investigational Site
-
Starachowice, Polonia
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Coimbra, Portogallo
- Boehringer Ingelheim Investigational Site
-
Lisboa, Portogallo
- Boehringer Ingelheim Investigational Site
-
Porto, Portogallo
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Leicester, Regno Unito
- Boehringer Ingelheim Investigational Site
-
Norwich, Regno Unito
- Boehringer Ingelheim Investigational Site
-
Sheffield, Regno Unito
- Boehringer Ingelheim Investigational Site
-
-
-
-
California
-
San Diego, California, Stati Uniti
- Boehringer Ingelheim Investigational Site
-
Torrance, California, Stati Uniti
- Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti
- Boehringer Ingelheim Investigational Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 40 anni a 75 anni (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion criteria:
- All patients must sign an informed consent consistent with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.
- All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria: Patients must have relatively stable airway obstruction with a post-bronchodilator forced expiratory volume in one second >=30% and <80% of predicted normal; Global Initiative for Chronic Obstructive Lung Disease grade II - III, and a post-bronchodilator Tiffeneau index <70% at Visit 1.
- Male or female patients, aged >=40 years and <=75 years.
- Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded.
Exclusion criteria:
- Patients with a significant disease other than chronic obstructive pulmonary disease.
- Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis.
- Patients with a history of asthma.
- A diagnosis of thyrotoxicosis.
- A diagnosis of paroxysmal tachycardia (>100 beats per minute).
- A history of myocardial infarction within 1 year of screening visit.
- Unstable or life-threatening cardiac arrhythmia.
- Hospitalized for heart failure within the past year.
- Known active tuberculosis.
- A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years.
- A history of life-threatening pulmonary obstruction and patients with chronic respiratory failure.
- A history of cystic fibrosis.
- Clinically evident bronchiectasis.
- A history of significant alcohol or drug abuse.
- Any contraindications for exercise testing.
- Patients who have undergone thoracotomy with pulmonary resection.
- Patients being treated with any oral ß-adrenergics.
- Patients being treated with oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
- Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigators opinion will be unable to abstain from the use of oxygen therapy during clinic visits.
- Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program.
- Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris or claudication or morbid obesity.
- Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to screening visit.
- Patients with known hypersensitivity to ß-adrenergics drugs, anticholinergic drugs, benzalkonium chloride, disodium edentat, or any other component of the Respimat® inhalation solution delivery system.
- Pregnant or nursing women.
- Women of childbearing potential not using highly effective methods of birth control.
- Patients who have previously been randomized in this study or are currently participating in another study.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: placebo
patient will receive placebo once daily, 2 puffs in the morning
|
comparator
|
|
Sperimentale: tiotropium + olodaterol high dose with BM
patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
|
olodaterol 5 mcg once daily fixed dose combination
|
|
Comparatore attivo: tiotropium
patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning
|
tiotropium 5 mcg once daily fixed dose combination
|
|
Sperimentale: tiotropium + olodaterol with exercise training and BM
patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
|
tiotropium 5 mcg once daily
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Endurance Time During Endurance Shuttle Walk Test (ESWT) to Symptom Limitation After 8 Weeks
Lasso di tempo: Week 8
|
Endurance time during ESWT to symptom limitation at walking speed corresponding to 85% of predicted maximum oxygen consumption (VO2 peak) after 8 weeks of pharmacological treatment and non-pharmacological intervention.
The numerical value of endurance time in seconds was transformed in log10 scale to correct for skewness and then an analysis of covariance (ANCOVA) was fitted to the log10-transformed data and the least square means (LSMean) and standard error (SE) were obtained.
To present the results in a way easier for interpretation, the least square mean from the ANCOVA fitted to the log10-transformed data were transformed back taking 10 to the power of the least square estimate to obtain the geometric mean and the corresponding SE was transformed using delta method to get the corresponding SE of the geometric mean.
|
Week 8
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Average Daily Walking Time Measured by the Activity Monitor in the Week Prior to Week 12
Lasso di tempo: Week 12
|
Average daily walking time measured by the activity monitor in the week prior to Week 12.
|
Week 12
|
|
Average Daily Walking Intensity Measured by the Activity Monitor in the Week Prior to 12 Weeks of Treatment
Lasso di tempo: Week 12
|
Average daily walking intensity measured by the activity monitor in the week prior to 12 weeks of treatment.
The Movement Intensity (MI) is derived from the acceleration signals.
Since seismic sensors measure gravitational acceleration (g) in static situations, the acceleration signal is expressed relative to g (1g = 9.81m/s2).
To calculate movement intensity (MI) the gravitational acceleration in static situations was removed and the rotation vector of the three accelerometer signals was calculated.
The MI gives an indication of the power of movements.
|
Week 12
|
|
Perceived Difficulties as Evaluated With Functional Performance Inventory-Short Form (FPI-SF) Total Score at Week 12
Lasso di tempo: Week 12
|
Perceived difficulties as evaluated with FPI-SF.
FPI-SF self-report questionnaire has 6 domains: Body care(5 items), Household maintenance(8 items), Physical exercise(5 items), Recreation(5 items), Spiritual activities(4 items) and Social interaction(5 items) with five possible answers on each item: Do with no difficulty - 3, Do with some difficulty - 2, Do with great difficulty - 1, don't do because of health reasons - 0, and don't do because choose not to - 0. Domain scores are expressed as mean values, with at least 6 non-missing items required for the household maintenance domain and at least 3 non-missing items for the other domains.
Total score is the mean across the six domains.
So total and domain scores range from 0 to 3, with higher scores indicating higher levels of functional activity within and across domains.
Respondents engaged in many activities with no difficulty will score high on the FPI, while those who perform few activities with much difficulty will score low.
|
Week 12
|
|
Endurance Time During Endurance Shuttle Walk Test (ESWT) to Symptom Limitation After 12 Weeks
Lasso di tempo: Week 12
|
Endurance time during ESWT to symptom limitation at walking speed corresponding to 85% of maximum oxygen consumption (VO2 peak) after 12 weeks of pharmacological treatment and non-pharmacological intervention.
The numerical value of endurance time in seconds was transformed in log10 scale to correct for skewness and then the ANCOVA was fitted to the log10-transformed data and the least square means and SE were obtained.
To present the results in a way easier for interpretation, the least square mean from the ANCOVA fitted to the log10-transformed data were transformed back taking 10 to the power of the least square estimate to obtain the geometric mean and the corresponding SE was transformed using delta method to get the corresponding SE of the geometric mean.
|
Week 12
|
|
One Hour, Post-dose Forced Expiratory Volume in One Second (FEV1) After 8 Weeks of Treatment
Lasso di tempo: Week 8
|
One hour, Post-dose Forced Expiratory Volume in One Second (FEV1) after 8 weeks of treatment.
|
Week 8
|
|
One Hour, Post-dose Forced Vital Capacity (FVC) After 8 Weeks of Treatment
Lasso di tempo: Week 8
|
One hour, Post-dose Forced Vital Capacity (FVC) after 8 weeks of treatment.
|
Week 8
|
|
Resting Inspiratory Capacity (IC) Measured at 1.5 Hours Post Dose After 8 Weeks of Treatment
Lasso di tempo: Week 8
|
Resting inspiratory capacity (IC) measured at 1.5 hours post dose after 8 weeks of treatment.
|
Week 8
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, Korducki L, Hamilton A. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. BMJ Open. 2016 Apr 13;6(4):e010106. doi: 10.1136/bmjopen-2015-010106.
- Bourbeau J, Lavoie KL, Sedeno M, De Sousa D, Erzen D, Hamilton A, Maltais F, Troosters T, Leidy N. Behaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementation. BMJ Open. 2016 Apr 4;6(4):e010109. doi: 10.1136/bmjopen-2015-010109.
Collegamenti utili
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 marzo 2014
Completamento primario (Effettivo)
1 agosto 2015
Completamento dello studio (Effettivo)
1 ottobre 2015
Date di iscrizione allo studio
Primo inviato
7 marzo 2014
Primo inviato che soddisfa i criteri di controllo qualità
7 marzo 2014
Primo Inserito (Stima)
12 marzo 2014
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
6 gennaio 2017
Ultimo aggiornamento inviato che soddisfa i criteri QC
9 novembre 2016
Ultimo verificato
1 novembre 2016
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie delle vie respiratorie
- Malattie polmonari, ostruttive
- Malattie polmonari
- Malattia polmonare, cronica ostruttiva
- Effetti fisiologici delle droghe
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Parasimpaticolitici
- Agenti autonomi
- Agenti del sistema nervoso periferico
- Antagonisti colinergici
- Agenti colinergici
- Agenti broncodilatatori
- Agenti antiasmatici
- Agenti del sistema respiratorio
- Tiotropio bromuro
- Olodaterolo
Altri numeri di identificazione dello studio
- 1237.16
- 2013-002671-18 (Numero EudraCT: EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .